CTI Sees Ideal Pipeline Acquisition In JAK2 Inhibitor Abandoned By Onyx
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell Therapeutics licenses Phase III pacritinib from Singapore’s S*BIO about a year after Onyx declined an option on the myelofibrosis candidate.
You may also be interested in...
CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line
The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.
Deals of the Week: Options Abound As Forest Keeps Its Eyes On A Prize-Winner
Reflecting a long trend, three of this past week’s deals include option arrangements, including one with a new twist. Also, a rare disease partnership between Shire and Atlas Venture finally leads to a deal and Takeda continues building its vaccines business.
Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.